

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**奧園健康生活集團有限公司**  
AOYUAN HEALTHY LIFE GROUP COMPANY LIMITED  
(Incorporated in the Cayman Islands with limited liability)  
(Stock Code: 3662)

**QUARTERLY UPDATE ON RESUMPTION PROGRESS**

This announcement is made by Aoyuan Healthy Life Group Company Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rules 13.09(2)(a) and 13.24A of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

References are made to (a) the inside information announcement of the Company dated 30 March 2022 in relation to, among others, the delay in the publication of the annual results of the Group and the despatch of the Company’s annual report for the financial year ended 31 December 2021; (b) the inside information announcement of the Company dated 3 May 2022 in relation to, among others, certain fund flows matters, the formation of the independent investigation committee of the Company and the appointment of independent professional advisors; (c) the inside information announcement of the Company dated 2 June 2022 in relation to, among others, the change of auditor of the Company and certain allegations against the Group; (d) the inside information announcement of the Company dated 30 June 2022 in relation to, among others, the resumption guidance issued by the Stock Exchange; and (e) the inside information announcement of the Company dated 31 August 2022 in relation to, among others, the delay in the publication of the preliminary results of the Group and the despatch of the Company’s interim report for the six months ended 30 June 2022 (collectively, the “**Announcements**”). Unless otherwise stated, terms used in this announcement shall have the same respective meanings as those defined in the Announcements.

## **UPDATE INFORMATION**

As disclosed in the announcement of the Company dated 30 June 2022, the Stock Exchange has set out the Resumption Guidance for the Company. The Company has continuously been making efforts in taking steps to fulfill the Resumption Guidance. In compliance with Rule 13.24A of the Listing Rules, the board of directors (the “**Board**”) of the Company would like to provide the Shareholders and potential investors of the Company with the following updates on the latest resumption progress as at the date of this announcement.

### **Business Operations**

The Group is principally engaged in the provision of the property management services and commercial operational services for properties developed or owned by the property developers in the People’s Republic of China. Notwithstanding the suspension of trading in the shares of the Company, the Group is carrying on its business operations as usual in all material respects and will continue to closely monitor its financial position and business operations.

### **Independent Investigations and Internal Control Review**

As at the date of this announcement, the Investigation Firm has completed the independent investigations in relation to (a) the issues 1 and 2 of the Fund Flows Matters and (b) the Allegations and is in the stage of finalizing the investigation reports. Subject to the issue of the investigation reports by the Investigation Firm, the Company will announce the key findings of the independent investigations as soon as practicable.

Further, the Company has engaged an internal control advisor to review the internal control of the Group, provide suggestions of remedial measures together with a work plan, and summarize the status of implementation of the remedial measures. As at the date of this announcement, the internal control review is still ongoing and the expected timing for the completion of the internal control review is yet to be determined at this stage. The Company will publish further announcements on any material developments as and when appropriate.

### **2021 Annual Results and 2022 Interim Results**

The auditor of the Company is still in the course of preparing the 2021 Annual Results and the 2022 Interim Results. The Board and the management of the Company have been working closely with its auditor to finalize and publish the 2021 Annual Results and the 2022 Interim Results and despatch the 2021 Annual Report and the 2022 Interim Report as soon as practicable.

## **Resumption Plan**

The Company is still in the process of devising and considering its resumption plan. In order to satisfy the requirements under the Resumption Guidance and the Listing Rules, the Company will continue to work with its professional advisors to advance the resumption progress.

The Company remains committed to the Resumption Guidance and will publish further announcement(s) to keep the Shareholders and potential investors of the Company informed of the status and development of the Company as and when appropriate, as well as announce quarterly updates on its development of the resumption status pursuant to Rule 13.24A of the Listing Rules.

## **CONTINUED SUSPENSION OF TRADING**

At the request of the Company, trading in the shares of the Company on the Stock Exchange has been suspended with effect from 9:00 a.m. on Friday, 1 April 2022 and will continue to be suspended until further notice.

By order of the Board  
**Aoyuan Healthy Life Group Company Limited**  
**Guo Zining**  
*Chairman*

Hong Kong, 30 September 2022

*As at the date of this announcement, the executive Director is Mr. Cheng Siu Fai; the non-executive Directors are Mr. Guo Zining and Mr. Ruan Yongxi; and the independent non-executive Directors are Mr. Hung Ka Hai Clement, Dr. Li Zijun and Mr. Wang Shao.*